X0306 4 2013-05-28 1 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001162059 HIRSCH RUSSELL C 435 TASSO STREET, SUITE 200 PALO ALTO CA 94301 1 0 0 0 Common Stock 2013-05-28 4 C 0 27237 A 27237 I Prospect Associates II, L.P. Common Stock 2013-05-28 4 C 0 1788647 A 1788647 I Prospect Venture Partners II, L.P. Series A Preferred Stock 2013-05-28 4 C 0 14558 0.00 D Common Stock 14558 0 I Prospect Associates II, L.P. Series A Preferred Stock 2013-05-28 4 C 0 956029 0.00 D Common Stock 956029 0 I Prospect Venture Partners II, L.P. Series B Preferred Stock 2013-05-28 4 C 0 5388 0.00 D Common Stock 5388 0 I Prospect Associates II, L.P. Series B Preferred Stock 2013-05-28 4 C 0 353839 0.00 D Common Stock 353839 0 I Prospect Venture Partners II, L.P. Series C Preferred Stock 2013-05-28 4 C 0 5675 0.00 D Common Stock 5675 0 I Prospect Associates II, L.P. Series C Preferred Stock 2013-05-28 4 C 0 372665 0.00 D Common Stock 372665 0 I Prospect Venture Partners II, L.P. Series D Preferred Stock 2013-05-28 4 C 0 1616 0.00 D Common Stock 1616 0 I Prospect Associates II, L.P. Series D Preferred Stock 2013-05-28 4 C 0 106114 0.00 D Common Stock 106114 0 I Prospect Venture Partners II, L.P. Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date. Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date. Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date. Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date. The shares are owned by PA II, which is under common control with PVP II. PMC II serves as the sole general partner of PA II. The Reporting Person is a Managing Director of PMC II. As such, the Reporting Person shares voting and investment power over the shares held by PA II and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. The shares are owned by Prospect Venture Partners II, L.P. ("PVP II"), which is under common control with Prospect Associates II, L.P. ("PA II"). Prospect Management Co. II, L.L.C. ("PMC II") serves as the sole general partner of PVP II. The Reporting Person is a Managing Director of PMC II. As such, the Reporting Person shares voting and investment power over the shares held by PVP II and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. The shares do not have an expiration date. /s/ Sally A. Kay, as attorney-in-fact 2013-05-28